Search Within

David Hyman

  1. "2018"
Formats
  1. Journal Article (36)
  2. Meeting Abstract (21)
Groups
  1. Department of Medicine (57)
  2. Early Drug Development Service (57)
  3. Solid Tumor Oncology Division (57)
  4. GSK Faculty (37)
  5. Department of Pathology and Laboratory Medicine (35)
  6. Human Oncology and Pathogenesis Program (31)

More Groups

People
  1. Michael Berger (23)
  2. David Solit (21)
  3. Ahmet Zehir (14)
  4. Jose Baselga (14)
  5. Marc Ladanyi (14)
  6. Alexander Drilon (12)

More People

Years
  1. 2018 (57)
Publications
  1. Journal of Clinical Oncology (11)
  2. Cancer Discovery (5)
  3. Cancer Research (5)
  4. Clinical Cancer Research (5)
  5. Cancer Cell (3)
  6. JAMA Oncology (3)

More Publications

Publishers
  1. American Association for Cancer Research (15)
  2. American Society of Clinical Oncology (13)
  3. Nature Publishing Group (5)
  4. American Medical Association (3)
  5. Cell Press (3)
  6. Lippincott Williams & Wilkins (3)

More Publishers

Results (57)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • PRECISE: A clinical-grade automated molecular eligibility screening and just-in-time (JIT) physician decision support solution for molecularly-selected oncology trials
    Meeting Abstract

    Tao, J.; Eubank, M. H.; Pamer, E.; Cangemi, N. A.; Drilon, A. E.; Harding, J. J.; Schram, A. M.; Smyth, L. M.; Jhaveri, K. L.; Li, B. T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers
    Meeting Abstract

    Li, B. T.; Makker, V.; Buonocore, D. J.; Offin, M. D.; Olah, Z. T.; Panora, E.; Shen, R.; Ho, A. L.; Yaeger, R.; Iyer, G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
    Meeting Abstract

    Hyman, D. M.; Brana, I.; Spreafico, A.; Schram, A. M.; Pandya, N. B.; Hoffman, K.; Hallet, R.; Giblin, P.; Anido, J.; Ruano, I. H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • The clinical utility of prospective molecular characterization in advanced cervical and vulvovaginal cancer
    Meeting Abstract

    Friedman, C. F.; Donoghue, M.; Vivek, M.; Aghajanian, C.; Abu-Rustum, N.; Cadoo, K. A.; Grisham, R. N.; Hensley, M. L.; Konner, J. A.; Kyi, C.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic landscape, clinical characteristics and outcomes of early onset (EO) compared with average onset (AO) colorectal cancer (CRC)
    Meeting Abstract

    Dos Santos Fernandes, G.; Chatila, W. K.; Yaeger, R.; Mendelsohn, R. B.; Stadler, Z. K.; Segal, N. H.; Varghese, A. M.; Lagunes, D. R.; Diaz, L. A.; Shia, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Prevalence of germline genetic alterations in colorectal cancer patients
    Meeting Abstract

    Cercek, A.; Kemel, Y.; Mandelker, D.; Stewart, C.; Arnold, A. G.; Sheehan, M.; Yaeger, R.; Segal, N. H.; Varghese, A. M.; Saltz, L. B.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • A phase 1 study of MDM2 inhibitor DS-3032b in patients with well/de-differentiated liposarcoma (WD/DD LPS), solid tumors (ST) and lymphomas (L)
    Meeting Abstract

    Bauer, T. M.; Gounder, M. M.; Weise, A. M.; Schwartz, G. K.; Carvajal, R. D.; Kumar, P.; Zernovak, O.; Beck, A.; Doyle, J.; Mendell-Harary, J.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Comprehensive detection of targetable fusions in lung adenocarcinomas by complementary targeted DNAseq and RNAseq assays
    Meeting Abstract

    Benayed, R.; Offin, M. D.; Mullaney, K. A.; Sukhadia, P.; Rios, K. M.; Desmeules, P.; Chang, J. C.; Hyman, D. M.; Berger, M. F.; Zehir, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic heterogeneity underlies mixed response to tropomyosin receptor kinase inhibition in recurrent glioma
    Journal Article

    Schram, A. M.; Jonsson, P.; Drilon, A.; Bale, T. A.; Hechtman, J. F.; Benayed, R.; Hanusch, B.; Young, R. J.; Grommes, C.; Ku, N.; more...
    JCO Precision Oncology (2018)

    Fulltext@MSK | Save
  • Safety and tolerability of the dual PI3K/mTOR inhibitor LY3023414 in treatment of patients with advanced mesothelioma
    Meeting Abstract

    Zauderer, M. G.; Hyman, D. M.; Alley, E. W.; Bendell, J. C.; Novello, S.; Bauer, T. M.; Hanauske, A. R.; Szpurka, A. M.; Kang, S.; Chatterjee, A.; more...
    Cancer Research (2018)

    Fulltext@MSK | Save